Defactinib Completed Phase 2 Trials for Lung Cancers / Lung Cancer Non-Small Cell Cancer (NSCLC) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01951690Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer